A history of variceal bleeding is associated with further bleeding under atezolizumab-bevacizumab in patients with HCC.
Edouard LarreyBertille CampionManon EvainPhilippe SultanikLorraine BlaiseHéloïse GiudicelliMathilde WagnerPhilippe CluzelMarika RudlerNathalie Ganne-CarriéDominique ThabutManon AllairePublished in: Liver international : official journal of the International Association for the Study of the Liver (2022)
Atezolizumab-bevacizumab treatment was associated with a higher risk of AVB compared to sorafenib. A history of AVB was associated with AVB during follow-up, which questions the use of bevacizumab in this setting.